TARSICIO GACHERU: Open Payments
NPI 1164854295 · COLUMBUS, OH. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$4,193 in 220 payments from 16 companies in 2025. Trend: 2023 $3,298 · 2024 $4,148 · 2025 $4,193
Food & beverage: $4,193
| Company | Payments | Amount |
|---|---|---|
| Vanda Pharmaceuticals Inc. | 27 | $693 |
| E.R. Squibb & Sons, L.L.C. | 37 | $690 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 33 | $638 |
| Teva Pharmaceuticals USA, Inc. | 22 | $463 |
| Otsuka America Pharmaceutical, Inc. | 19 | $357 |
| Neurocrine BioSciences, Inc. | 14 | $315 |
| ABBVIE INC. | 27 | $306 |
| Lundbeck LLC | 16 | $227 |
| Axsome Therapeutics, Inc. | 8 | $136 |
| Indivior Inc. | 3 | $86 |
Products named: COBENFY, CAPLYTA, HETLIOZ, REXULTI, INGREZZA, VRAYLAR, UZEDY, FANAPT.
Industry payments across OH — which companies pay providers there.
